Market Cap (In NOK)
65.11 Million
Revenue (In NOK)
354 Thousand
Net Income (In NOK)
-190.4 Million
Avg. Volume
700.66 Thousand
- Currency
- NOK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.621-35.8
- PE
- -0.42
- EPS
- -3.95
- Beta Value
- 1.639
- ISIN
- NO0010650013
- CUSIP
- -
- CIK
- -
- Shares
- 39087100.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Martin Olin
- Employee Count
- -
- Website
- https://www.bergenbio.com
- Ipo Date
- 2017-04-07
- Details
- BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
More Stocks
-
TD-PFA
-
KOG
-
688110Dosilicon Co., Ltd.
688110
-
GALADAFINGalada Finance Limited
GALADAFIN
-
CFF
-
688659
-
IR5B
-
OBRNOberon Uranium Corp.
OBRN